5:35 PM
 | 
Dec 07, 2012
 |  BC Extra  |  Clinical News

Myriad reports analysis of HRD assay for breast cancer patients

Myriad Genetics Inc. (NASDAQ:MYGN) and researchers at Stanford University School of Medicine presented data on Friday from an analysis of the company's Homologous Recombination Deficiency (HRD) assay in 77 tumors from 76 breast cancer patients. The assay measures the number of defective breast cancer 1 early onset (BRCA1) and...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >